{"entity":{"id":"nct07644039","kind":"trial","name":"Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by PharmaMar, now recruiting.","summary":"Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies is a phase 1/2 interventional study registered as NCT07644039 by PharmaMar, with 119 participants planned, started 2026-05-21 and due to reach its primary completion in 2029-04-02. Interventions recorded: Pembrolizumab and PM54.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07644039","url":"https://clinicaltrials.gov/study/NCT07644039"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":["pharmamar"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07644039","phase":"1/2","setting":"A Multicenter, Open-label, Phase 1/2 Safety Run-in and Expansion Study of PM54 in Combination With Immunotherapy Evaluating Safety and Efficacy in Adult Participants Who Were Previously Treated for Advanced Malignancies","sponsor":"PharmaMar","enrolled":119,"outcomes":[]},"route":"/trials/nct07644039/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"pharmamar","kind":"company","name":"PharmaMar","route":"/companies/pharmamar/"}]}}